Abstract

BackgroundTranscriptome analysis by microarrays has produced important advances in biomedicine. For instance in multiple myeloma (MM), microarray approaches led to the development of an effective disease subtyping via cluster assignment, and a 70 gene risk score. Both enabled an improved molecular understanding of MM, and have provided prognostic information for the purposes of clinical management. Many researchers are now transitioning to Next Generation Sequencing (NGS) approaches and RNA-seq in particular, due to its discovery-based nature, improved sensitivity, and dynamic range. Additionally, RNA-seq allows for the analysis of gene isoforms, splice variants, and novel gene fusions. Given the voluminous amounts of historical microarray data, there is now a need to associate and integrate microarray and RNA-seq data via advanced bioinformatic approaches.MethodsCustom software was developed following a model-view-controller (MVC) approach to integrate Affymetrix probe set-IDs, and gene annotation information from a variety of sources. The tool/approach employs an assortment of strategies to integrate, cross reference, and associate microarray and RNA-seq datasets.ResultsOutput from a variety of transcriptome reconstruction and quantitation tools (e.g., Cufflinks) can be directly integrated, and/or associated with Affymetrix probe set data, as well as necessary gene identifiers and/or symbols from a diversity of sources. Strategies are employed to maximize the annotation and cross referencing process. Custom gene sets (e.g., MM 70 risk score (GEP-70)) can be specified, and the tool can be directly assimilated into an RNA-seq pipeline.ConclusionA novel bioinformatic approach to aid in the facilitation of both annotation and association of historic microarray data, in conjunction with richer RNA-seq data, is now assisting with the study of MM cancer biology.

Highlights

  • Transcriptome analysis by microarrays has produced important advances in biomedicine

  • Patient survival has improved dramatically in the past 10-15 years, due to scientific and technological advances, which have enabled an improved understanding of the cancer biology

  • Given our current and historical work involving microarray technology and disease focus at MIRT (Myeloma Institute for Research and Therapy), a review of key microarray experiments and the cancer biology gleaned was cataloged and studied

Read more

Summary

Introduction

Transcriptome analysis by microarrays has produced important advances in biomedicine. For instance in multiple myeloma (MM), microarray approaches led to the development of an effective disease subtyping via cluster assignment, and a 70 gene risk score Both enabled an improved molecular understanding of MM, and have provided prognostic information for the purposes of clinical management. Patient survival has improved dramatically in the past 10-15 years, due to scientific and technological advances, which have enabled an improved understanding of the cancer biology This has led to two new classes of medications, (Immunomodulatory drugs (IMiDs), e.g., thalidomide, lenalidomide, pomalidomide; and proteasome inhibitors, e.g., bortezomib, carfilzomib), new therapeutic approaches (e.g., autologous tandem transplant), and advances in cancer-based supportive care (e.g., bisphosphonates for bone metastasis) [8,9,10]

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call